Teacher Retirement System of Texas Invests $13.50 Million in Tempus AI, Inc. (NASDAQ:TEM)

Teacher Retirement System of Texas purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 400,000 shares of the company’s stock, valued at approximately $13,504,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the 3rd quarter valued at approximately $30,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI in the 4th quarter valued at approximately $34,000. FNY Investment Advisers LLC acquired a new stake in Tempus AI in the 4th quarter valued at approximately $67,000. IFP Advisors Inc acquired a new stake in Tempus AI in the 4th quarter valued at approximately $76,000. Finally, US Bancorp DE acquired a new stake in Tempus AI in the 4th quarter valued at approximately $80,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

TEM has been the topic of a number of recent research reports. Guggenheim reissued a “buy” rating on shares of Tempus AI in a research report on Tuesday, February 25th. TD Cowen restated a “buy” rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Morgan Stanley raised their price target on Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. JPMorgan Chase & Co. downgraded Tempus AI from an “overweight” rating to a “neutral” rating and raised their price target for the company from $50.00 to $55.00 in a research note on Tuesday, February 25th. Finally, Needham & Company LLC raised their price target on Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $61.18.

Insider Transactions at Tempus AI

In related news, COO Ryan Fukushima sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the sale, the chief operating officer now directly owns 982,442 shares in the company, valued at $38,914,527.62. The trade was a 2.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $35.10, for a total value of $9,301,500.00. Following the completion of the sale, the insider now owns 15,218,365 shares of the company’s stock, valued at $534,164,611.50. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,598,969 shares of company stock worth $317,194,162.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $51.35 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $91.45. The stock has a 50 day moving average of $56.35 and a 200-day moving average of $51.40.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.